Renal and Auditory toxic effects of amikacin in children with cancer.
Amikacin sulfate was given to 21 febrile children with neutropenia and cancer for 9 +/- 3 days. Peak serum amikacin levels ranged between 13 and 32 microgram/mL, and trough levels were consistently less than 2 microgram/mL. Renal toxic effects were detected in two children (9.5%) and were extremely mild. Two additional children (16.5%) experienced mild, transient, unilateral, high-frequency hearing losses. The lack of serious renal and auditory impairment suggests that children are at less risk than adults from aminoglycoside therapy.
D000293:Adolescent; D000583:Amikacin / Q000009:adverse effects*; D001424:Bacterial Infections / Q000150:complications / Q000188:drug therapy; D002648:Child; D002675:Child, Preschool; D034381:Hearing Loss / Q000139:chemically induced*; D006316:Hearing Loss, High-Frequency / Q000139:chemically induced; D006801:Humans; D007223:Infant; D007612:Kanamycin / Q000031:analogs & derivatives*; D007674:Kidney Diseases / Q000139:chemically induced*; D009369:Neoplasms / Q000150:complications*
D007612:Kanamycin; D000583:Amikacin